share_log

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target

HC Wainwright & Co.重申买入锐佳制药,维持15美元的目标股价
Benzinga ·  05/08 09:37

HC Wainwright & Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and maintains $15 price target.

HC韦恩莱特证券公司的分析师Joseph Pantginis重申了Rigel Pharmaceuticals(纳斯达克:RIGL)的买入评级,维持15美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发